115 related articles for article (PubMed ID: 20305130)
1. Contralateral second breast cancers: prediction and prevention.
Brenner DJ
J Natl Cancer Inst; 2010 Apr; 102(7):444-5. PubMed ID: 20305130
[No Abstract] [Full Text] [Related]
2. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study.
Bernstein JL; Haile RW; Stovall M; Boice JD; Shore RE; Langholz B; Thomas DC; Bernstein L; Lynch CF; Olsen JH; Malone KE; Mellemkjaer L; Borresen-Dale AL; Rosenstein BS; Teraoka SN; Diep AT; Smith SA; Capanu M; Reiner AS; Liang X; Gatti RA; Concannon P;
J Natl Cancer Inst; 2010 Apr; 102(7):475-83. PubMed ID: 20305132
[TBL] [Abstract][Full Text] [Related]
3. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
5. Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.
Garber JE; Golshan M
J Clin Oncol; 2009 Dec; 27(35):5862-4. PubMed ID: 19858367
[No Abstract] [Full Text] [Related]
6. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
7. The twists and turns in BRCA's path.
Couzin J
Science; 2003 Oct; 302(5645):591-3. PubMed ID: 14576418
[No Abstract] [Full Text] [Related]
8. Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.
Bernstein JL; Langholz B; Haile RW; Bernstein L; Thomas DC; Stovall M; Malone KE; Lynch CF; Olsen JH; Anton-Culver H; Shore RE; Boice JD; Berkowitz GS; Gatti RA; Teitelbaum SL; Smith SA; Rosenstein BS; Børresen-Dale AL; Concannon P; Thompson WD;
Breast Cancer Res; 2004; 6(3):R199-214. PubMed ID: 15084244
[TBL] [Abstract][Full Text] [Related]
9. Biomedicine. D-Day for BRCA2.
Witt E; Ashworth A
Science; 2002 Jul; 297(5581):534. PubMed ID: 12065747
[No Abstract] [Full Text] [Related]
10. Histopathological features of breast cancer in carriers of ATM gene variants.
Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
12. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
13. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
14. ATM and breast cancer susceptibility.
Ahmed M; Rahman N
Oncogene; 2006 Sep; 25(43):5906-11. PubMed ID: 16998505
[TBL] [Abstract][Full Text] [Related]
15. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
16. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Narod SA
Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
[TBL] [Abstract][Full Text] [Related]
17. [Genetic alterations and expression changes in breast cancers].
Terada K; Ushijima T
Nihon Rinsho; 2007 Jun; 65 Suppl 6():113-9. PubMed ID: 17682148
[No Abstract] [Full Text] [Related]
18. [Ataxia-telangiectasia mutated gene and breast cancer susceptibility].
Zhang N; Che J; Bai S; Wu Z; Cui Y; Zou W
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):9-15. PubMed ID: 20353086
[TBL] [Abstract][Full Text] [Related]
19. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
